Skylar Jeremias

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.

Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.

Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.

Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.

A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.

This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.

Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.

Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.

In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.

Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.

Wet work harms the skin barrier and microbiome as delgocitinib emerges.

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.

Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.

Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.

Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.

Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.

Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.

Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.

Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg

GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.

Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.